Wentilactone A reverses the NFκB/ECM1 signaling-induced cisplatin resistance through the inhibition of IKK/IκB in ovarian cancer cells, which provides the possibility of cooperation with cisplatin to improve the cancer patient survival. This evidence concerns the gene ECM1 and ovarian carcinoma.